Download Files:
SID 26681509 (quarterhydrate)
$195 – $980
Products Details
Product Description
– SID 26681509 quarterhydrate is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 quarterhydrate inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 quarterhydrate shows no inhibitory activity against cathepsin G[1].
Web ID
– HY-103353A
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C27H33N5O5S.1/4H2O
Citations
– Signal Transduct Target Ther. 2023 Oct 11;8(1):390.|Nat Commun. 2020 Mar 27;11(1):1620.|Nat Commun. 2022 May 26;13(1):2935.|Signal Transduct Target Ther. 2021 Mar 27;6(1):134.
References
– [1]Shah PP, et al. Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L. Mol Pharmacol. 2008 Jul;74(1):34-41.|[2]Pribis JP, et al. The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88. Mol Med. 2015 Dec;21(1):749-757.
Molecular Weight
– 544.16
Compound Purity
– 97.0
SMILES
– O=C(NNC(SCC(NC1=CC=CC=C1CC)=O)=O)[C@H](CC2=CNC3=CC=CC=C23)NC(OC(C)(C)C)=O.[1/4].O
Clinical Information
– No Development Reported
Research Area
– Cancer; Infection
Solubility
– DMSO : 50 mg/mL (ultrasonic)|Ethanol : 5 mg/mL (ultrasonic;warming)
Target
– Cathepsin;Parasite
Isoform
– Cathepsin L;Leishmania;Plasmodium
Pathway
– Anti-infection;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
